

Claims:

1. An adhesive patch suitable for the transdermal administration of granisetron, wherein the adhesive is an acrylic adhesive containing non-acidic hydroxyl moieties.
2. A patch according to claim 1, wherein the non-acidic hydroxyl moieties are provided by suitably selected comonomers. the simple expedient of incorporating the appropriate monomers during manufacture of the adhesive polymer.
3. A patch according to claim 2, wherein the selected comonomers are selected from substituted acrylates and methacrylates.
4. A patch according to claim 3, wherein the acrylate is selected from the hydroxymethyl, hydroxyethyl and hydroxypropyl acrylates.
5. A patch according to claim 3, wherein the methacrylate is selected from the hydroxymethyl and hydroxyethyl methacrylates.
6. A patch according to any preceding claim, which is pressure sensitive.
7. A patch according to any preceding claim, containing a major amount of a primary acrylate monomer.
8. A patch according to claim 7, wherein the primary acrylate monomer is either 2-ethylhexyl acrylate or butyl acrylate.
9. A patch according to any preceding claim, adapted to provide a pharmacologically effective amount of granisetron or ramosetron after about 2 hours.
10. A patch according to any preceding claim, comprising up to about 10% by weight of granisetron or ramosetron.

11. A patch according to claim 10, having less than 8% w/w granisetron or ramosetron.
12. A patch according to any preceding claim, having a level of granisetron or ramosetron above 4% w/w.
13. A patch according to claim 10, having a level of between 6% and 7.7% w/w of granisetron or ramosetron.
14. A patch according to any preceding claim, wherein no crystallisation is observed after one month storage at room temperature and pressure.
15. A patch according to any preceding claim and comprising granisetron or ramosetron, for the treatment of chemically induced emesis.
16. A patch according to claim 9, wherein the emesis is acute.
17. A patch according to claim 9, wherein the emesis is delayed.
18. A patch according to any of claims 1 to 14 and comprising granisetron, for the treatment of emesis associated with fractionated chemotherapy
19. A patch according to any of claims 1 to 14 and comprising granisetron or ramosetron, for the treatment and prophylaxis of postoperative nausea and vomiting.
20. A patch according to any of claims 1 to 14 and comprising granisetron or ramosetron, for the treatment and prophylaxis of nausea and vomiting associated with radiotherapy.
21. A patch according to any of claims 1 to 14 and comprising granisetron or ramosetron, for the treatment and prophylaxis of nausea and vomiting associated with fractionated cancer therapy.

22. A patch according to any of claims 1 to 14 and comprising granisetron or ramosetron, for the treatment and prophylaxis of a condition selected from; pruritus, fibromyalgia and pain associated therewith, migraine, anxiety, cognitive and psychotic disorders, depression, schizophrenia, psychosis in postnatal depression, irritable bowel syndrome, alcoholism, obstructive sleep disturbed breathing, motion sickness, loss of cognitive function such as Alzheimer's, urinary incontinence, dyskinesia, systemic lupus erythematosus, drug-induced pruritus, premature ejaculation, eating disorders, obsessive compulsive disorder, gastric motility disorders, chronic fatigue syndrome, dyspepsia and cocaine dependence.
23. A patch according to any preceding claim, wherein the adhesive is loaded with between 3 and 12% w/w granisetron or ramosetron.
24. A patch according to claim 23, wherein the adhesive is loaded with between 4 and 10% w/w granisetron or ramosetron.
25. A patch according to claim 23, wherein the adhesive is loaded with between 5 and 8% w/w granisetron or ramosetron.
26. A patch according to any preceding claim, wherein the active ingredient is granisetron.
27. A patch according to any of claims 1 to 25, wherein the active ingredient is ramosetron.
28. A patch according to any preceding claim, wherein, at an adhesive loading of 6% w/w of active ingredient, the adhesive has a surface area of between 10 and 100 cm².
29. A patch according to claim 28, wherein the adhesive has a surface area of between 15 and 50 cm².

30. A method for the treatment of a condition associated with 5-HT₃ receptor activity in a patient in need thereof, comprising administering an adhesive patch according to any preceding claim to the skin of the patient.